昆药集团 (600422)
KPC Pharmaceuticals, Inc.
K-Line Chart
No K-line data available
Company NameKunming Pharmaceutical Group Co., Ltd.
Listing Date2000-12-06
Issue Price10.22RMB
Registered Capital75697.575710k RMB
Legal RepresentativeYan Wei
Registered AddressNo. 166 Keyi Road, National High-Tech Industrial Development Zone, Kunming City, Yunnan Province, China
IndustryTraditional Chinese Medicine II
Main BusinessProduction and operation of natural medicines, wholesale and retail of externally purchased drugs.
Company ProfileKunming Pharmaceutical Group Co., Ltd. (referred to as Kunyao Group, 600422 SH) was established in March 1951 and listed on the Shanghai Stock Exchange in 2000. The company possesses profound professional pharmaceutical experience and is a National Key High-Tech Enterprise and one of China's Top 100 Pharmaceutical Industrial Enterprises. Its proprietary brands such as Luotai®, Tianxuanqing®, Artemedine®, Artem®, and Arco® enjoy a high reputation both domestically and internationally.
Kunyao Group integrates drug R&D, production, sales, commercial wholesale, and international marketing, forming a business structure primarily focused on proprietary natural botanical drugs, covering traditional Chinese medicine, chemical drugs, and pharmaceutical distribution. Its subsidiaries and associated companies include Kunming Traditional Chinese Medicine Factory Co., Ltd., Kunyao Group Xuesaitong Pharmaceutical Co., Ltd., Xishuangbanna Banna Pharmaceutical Co., Ltd., Kunyao Group Pharmaceutical Commercial Co., Ltd., Kunming Baker Norton Pharmaceutical Co., Ltd., Kunyao Group Nukus Botanical Technology Co., Ltd., Kunming Yinnuo Pharmaceutical Technology Co., Ltd., Beijing Huafang Ketai Pharmaceutical Co., Ltd., etc. It also possesses large-scale manufacturing centers, the Xuesaitong Drug Research Institute, and a postdoctoral workstation. The "Kunyao Biomedicine Technology Park," located in the National Bio-industry Base of Kunming High-tech Zone, upon completion, will become a world-leading, domestically first-class, large-scale, specialized, and international biomedicine park.
Stock Details
1. Key Indicators
- Total Shares(W): 75697.58
- Circulating A-Shares(W): 75697.58
- Earnings Per Share(RMB): 0.3600
- Net Assets Per Share(RMB): 7.0132
- Operating Revenue(W RMB): 475120.61
- Total Profit(W RMB): 37842.11
- **Net Profit Attributable to Parent(W RMB) **: 26936.78
- Net Profit Growth Rate(%): -30.47
- Weighted Return on Equity(%): 5.0700
- Operating Cash Flow Per Share(RMB): 0.2330
- Undistributed Profit Per Share(RMB): 4.8312
- Capital Reserve Per Share(RMB): 0.6879
2. Main Business
The main business covers:
- Research, development, production and sales of natural botanical medicines
3. Company Basic Information
- Company Name: Kunming Pharmaceutical Group
- Listing Date: Unknown
- Industry: Pharmaceutical Manufacturing
- Address: Unknown
- Website: Unknown
- Company Profile: The company focuses on the research, development, production and sales of natural botanical medicines.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. | General Legal Person | 21231.16 | 28.05 |
| 2 | Yunnan Hehe (Group) Co., Ltd. | General Legal Person | 5998.27 | 7.92 |
| 3 | National Social Security Fund 406 Portfolio | Social Security Fund | 1435.13 | 1.90 |
| 4 | Fullgoal Research Selected Flexible Allocation Mixed Securities Investment Fund Class A | Fund | 1389.26 | 1.84 |
| 5 | Central Huijin Asset Management Co., Ltd. | Special Legal Person | 1181.49 | 1.56 |
| 6 | Monetary Authority of Macao - Own Funds | QFII | 976.97 | 1.29 |
| 7 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 920.93 | 1.22 |
| 8 | Invesco Great Wall Resource Monopoly Mixed Securities Investment Fund (LOF) Class A | Fund | 840.52 | 1.11 |
| 9 | Kuwait Investment Authority - Own Funds | QFII | 638.11 | 0.84 |
| 10 | Invesco Great Wall China Return Flexible Allocation Mixed Securities Investment Fund Class A | Fund | 572.77 | 0.76 |
5. Concept Sectors
- Traditional Chinese Medicine
- Pharmaceuticals
Remarks
- Data update date: 2025-09-30
- Data source: Public market information